Ferric citrate - Keryx Biopharmaceuticals

Drug Profile

Ferric citrate - Keryx Biopharmaceuticals

Alternative Names: Auryxia; Ferric citrate dihydrate; Fexeric; JTT-751; KRX-0502; Nephoxil; Riona; Tetraferric tricitrate decahydrate; Zerenex

Latest Information Update: 09 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Panacor Bioscience; Panion & BF Biotech
  • Developer Japan Tobacco; Keryx Biopharmaceuticals; Panion & BF Biotech; Torii Pharmaceutical
  • Class Antianaemics; Ferric compounds; Hyperphosphataemia therapies; Small molecules; Tricarboxylic acids
  • Mechanism of Action Iron replacements; Phosphate binding protein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Hyperphosphataemia
  • Registered Iron deficiency anaemia

Most Recent Events

  • 07 Nov 2017 Registered for Iron deficiency anaemia (In adults) in USA (PO)
  • 19 Sep 2017 Japan Tobacco completes a phase II trial in Iron deficiency anaemia in Japan (PO), before September 2017 (JapicCTI-163311)
  • 18 Jul 2017 Japan Tobacco completes a phase I trial in Iron deficiency anaemia in Japan, before July 2017 (JapicCTI-173502)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top